TITLE

BIOLINERX GETS RESULTS FROM PHASE I/II TRIAL OF BL-5010

PUB. DATE
February 2011
SOURCE
Worldwide Biotech;Feb2011, Vol. 23 Issue 2, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the completion of the Phase I/II clinical trial of BioLineRx's BL-5010 skin lesion treatment. Conducted in 60 individuals diagnosed with seborrheic ketatosis in Germany and the Netherlands, the trial aims to examine the effectiveness and safety of BL-5010 for removing skin lesions. Researchers found that 96.7 percent of the patients saw that their lesions were removed within 30 days of a single application of the drug.
ACCESSION #
57671636

 

Related Articles

  • BioLineRx Announces European Confirmation of Medical Device Regulatory Pathway for BL-5010, for Non-surgical Removal of Skin Lesions.  // Biomedical Market Newsletter;9/26/2011, Vol. 21, p1002 

    The article reports on the confirmation received by BioLineRx Ltd. for the development of BL-5010, a formulation for the removal of benign skin lesion from the British Standards Institution Notified Body (BSI) in Great Britain. It states that the confirmation reduces the time and resources...

  • Striking gold for AKs? Petrou, Ilya // Dermatology Times;Nov2008, Vol. 29 Issue 11, p92 

    The article reports on the clinical trials for ingenol mebutate drug in the treatment of actinic keratosis (AK) in the U.S. Trials reveal that ingenol mebutate is safe and effective in the treatment of AK. Dermatologist Lawrence Anderson believes that ingenol mebutate has the potential to treat...

  • Telavancin: A novel lipoglycopeptide antibiotic. Damodaran, S. E.; Madhan, S. // Journal of Pharmacology & Pharmacotherapeutics;Apr2011, Vol. 2 Issue 2, p135 

    The article focuses on the efficacy of telavancin as lipoglycopeptide antibiotics, approved for the treatment of complicated skin and skin structure infections (cSSSI) caused by Gram positive organisms. It says that the Assessment of Telavancin in Complicated Skin and Skin Structure Infections...

  • Basilea Pharmaceutica: alitretinoin could be safer alternative.  // PharmaWatch: Monthly Review;Jun2007, Vol. 6 Issue 6, p19 

    The article reports on the effectivity of the dermatology drug alitretinoin in treating severe chronic hand dermatitis. It is stated that the second phase III clinical trial conducted by the Swiss pharmaceutical company Basilea Pharmaceutica AG, for its alitretinoin has shown positive results....

  • Comparison of efficacy of Azithromycin vs. Clindamycin and Erythromycin in the treatment of mild to moderate acne vulgaris. Hajheydari, Zohre; Mahmoudi, Mitra; Vahidshahi, Korosh; Nozari, Arezoo // Pakistan Journal of Medical Sciences;2011, Vol. 27 Issue 1, p68 

    Objective: Acne vulgaris is a prevalent inflammatory skin disorder. Topical solutions of clindamycin and erythromycin are the most common treatment in the patients. This study was conducted to compare the effect of topical solution azithromycin as a new method of treatment against topical...

  • CLINIC ROUNDUP.  // BioWorld Today;3/25/2008, Vol. 19 Issue 58, p6 

    This section offers news briefs on clinical trials related to biotechnology. The Phase III clinical trial of SinuNase by Accentia Biopharmaceuticals Inc. has achieved superior resolution of the cardinal symptoms of chronic sinusitis. The Fluocinolone Acetonide in Diabetic Macular Edema Study by...

  • CLINIC ROUNDUP.  // BioWorld Today;5/5/2008, Vol. 19 Issue 87, p3 

    This section offers news briefs on clinical trials results released by biopharmaceutical companies as of May 5, 2008. BioLineRx Ltd. has released data demonstrating the effectiveness of the drug BL-1020. Celgene Cellular Therapeutics has announced the successful transplantation of human...

  • Phase II Clinical Trials Update: September 2013.  // BioWorld Insight;10/14/2013, Vol. 21 Issue 42, p12 

    A table is presented which lists the biotechnology companies' phase II clinical trials updates as of September 2013 which includes Agenus Inc., Biolinerx Ltd., and Aesrx LLC.

  • BioLineRx Gets BL-4040 Rights; Delves Into Acute Kidney Injury. Boggs, Jennifer // BioWorld Today;8/28/2007, Vol. 18 Issue 167, p1 

    This article reports on the acquisition of rights by BioLineRx Ltd. to a genetically-engineered version of the capsid protein VP1, a compound believed to have potential in protecting cells following acute kidney injury. BioLineRx entered a worldwide agreement with Gene Vector Technologies Ltd....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics